Viglianti Elizabeth M, Zajic Paul, Iwashyna Theodore J, Amrein Karin
Department of Internal Medicine, Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI, USA.
Department of Anesthesiology and Intensive Care Medicine, Division of General Anesthesiology, Emergency and Intensive Care Medicine, Medical University of Graz, Graz, Austria.
Crit Care Resusc. 2019 Mar;21(1):39-44.
The purpose of this study was to evaluate if vitamin D deficiency is associated with increased rates of persistent critical illness, and whether repletion of vitamin D among patients with this deficiency leads to decreased persistent critical illness.
Retrospective cohort analysis.
Seven intensive care units (ICUs) at the University Medical Center of Graz, Austria, with participants recruited between July 2008 and April 2010. The VITdAL-ICU trial cohort included five ICUs at the University Medical Center of Graz, Austria, with patients recruited between May 2010 through September 2012.
There were 628 patients aged ≥ 18 years admitted to the ICU and who had their 25-hydroxyvitamin D (25(OH)D) level measured at least once. The VITdAL-ICU cohort included 475 patients aged ≥ 18 years who were expected to stay in the ICU for greater than 48 hours and found to have a 25(OH)D level of ≤ 20 ng/mL.
Development of persistent critical illness.
In the retrospective cohort, vitamin D level on admission was not significantly associated with the development of persistent critical illness compared with patients who were discharged alive earlier (relative risk ratio [RRR], 1.02; 95% CI, 1.00-1.04) or who died (RRR, 1.02; 95% CI, 0.99-1.05). In the VITdAL-ICU trial, supplementation with vitamin D3 did not lead to less persistent illness relative to patients who were discharged alive earlier (RRR, 1.19; 95% CI, 0.79-1.80) or who died (RRR, 1.34; 95% CI, 0.72-2.52).
Vitamin D deficiency was not associated with persistent critical illness, nor did supplementation with vitamin D3 mitigate the development of persistent critical illness.
本研究旨在评估维生素D缺乏是否与持续性危重病发生率增加相关,以及维生素D缺乏患者补充维生素D是否会降低持续性危重病的发生率。
回顾性队列分析。
奥地利格拉茨大学医学中心的七个重症监护病房(ICU),研究对象于2008年7月至2010年4月招募。VITdAL-ICU试验队列包括奥地利格拉茨大学医学中心的五个ICU,患者于2010年5月至2012年9月招募。
628名年龄≥18岁入住ICU且至少测量过一次25-羟基维生素D(25(OH)D)水平的患者。VITdAL-ICU队列包括475名年龄≥18岁、预计在ICU停留超过48小时且25(OH)D水平≤20 ng/mL的患者。
持续性危重病的发生情况。
在回顾性队列中,与较早存活出院的患者(相对风险比[RRR],1.02;95%可信区间[CI],1.00 - 1.04)或死亡患者(RRR,1.02;95%CI,0.99 - 1.05)相比,入院时的维生素D水平与持续性危重病的发生无显著相关性。在VITdAL-ICU试验中,相对于较早存活出院的患者(RRR,1.19;95%CI,0.79 - 1.80)或死亡患者(RRR,1.34;95%CI,0.72 - 2.52),补充维生素D3并未导致持续性疾病减少。
维生素D缺乏与持续性危重病无关,补充维生素D3也不能减轻持续性危重病的发生。